Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma.

Locati LD, Serafini MS, Iannò MF, Carenzo A, Orlandi E, Resteghin C, Cavalieri S, Bossi P, Canevari S, Licitra L, De Cecco L.

Cancers (Basel). 2019 Jul 26;11(8). pii: E1057. doi: 10.3390/cancers11081057.

2.

Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.

Frigerio B, Morlino S, Luison E, Seregni E, Lorenzoni A, Satta A, Valdagni R, Bogni A, Chiesa C, Mira M, Canevari S, Alessi A, Figini M.

J Exp Clin Cancer Res. 2019 Jul 23;38(1):326. doi: 10.1186/s13046-019-1325-6.

3.

A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes.

De Cecco L, Serafini MS, Facco C, Granata R, Orlandi E, Fallai C, Licitra L, Marchesi E, Perrone F, Pilotti S, Quattrone P, Piazza C, Sessa F, Turri-Zanoni M, Battaglia P, Castelnuovo P, Antognoni P, Canevari S, Bossi P.

Oral Oncol. 2019 Mar;90:94-101. doi: 10.1016/j.oraloncology.2019.02.003. Epub 2019 Feb 11.

4.

The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.

Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S.

Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3.

5.

Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.

Canese R, Palombelli G, Chirico M, Sestili P, Bagnoli M, Canevari S, Mezzanzanica D, Podo F, Iorio E.

NMR Biomed. 2018 Oct 30:e4016. doi: 10.1002/nbm.4016. [Epub ahead of print]

PMID:
30375088
6.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN.

Clin Cancer Res. 2018 Oct 15;24(20):5098-5111. doi: 10.1158/1078-0432.CCR-18-0652. Epub 2018 Aug 1.

7.

Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.

Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, Kourtidis A, Anastasiadis PZ, Tomassetti A.

J Exp Clin Cancer Res. 2018 Jul 11;37(1):146. doi: 10.1186/s13046-018-0796-1.

8.

Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann RE, Iacovelli F, Desideri A, Anichini A, Canevari S, Gianni AM, Figini M.

MAbs. 2018 Oct;10(7):1084-1097. doi: 10.1080/19420862.2018.1494105. Epub 2018 Aug 6.

9.

Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.

Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L.

Oral Oncol. 2018 Jul;82:144-151. doi: 10.1016/j.oraloncology.2018.05.013. Epub 2018 May 28.

PMID:
29909889
10.

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

Josephs DH, Nakamura M, Bax HJ, Dodev TS, Muirhead G, Saul L, Karagiannis P, Ilieva KM, Crescioli S, Gazinska P, Woodman N, Lombardelli C, Kareemaghay S, Selkirk C, Lentfer H, Barton C, Canevari S, Figini M, Downes N, Dombrowicz D, Corrigan CJ, Nestle FO, Jones PS, Gould HJ, Blower PJ, Tsoka S, Spicer JF, Karagiannis SN.

Allergy. 2018 Dec;73(12):2328-2341. doi: 10.1111/all.13455. Epub 2018 Oct 8.

11.

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement PM, Coropciuc R, Hauben E, Licitra LF.

Ann Oncol. 2018 Apr 1;29(4):985-991. doi: 10.1093/annonc/mdy013.

PMID:
29346507
12.

Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?

Bossi P, Siano M, Bergamini C, Cossu Rocca M, Sponghini AP, Giannoccaro M, Tonella L, Paoli A, Marchesi E, Perrone F, Pilotti S, Locati LD, Canevari S, Licitra L, De Cecco L.

Dis Markers. 2017;2017:6870614. doi: 10.1155/2017/6870614. Epub 2017 Nov 12.

13.

Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.

Paris L, Podo F, Spadaro F, Abalsamo L, Pisanu ME, Ricci A, Cecchetti S, Altabella L, Buoncervello M, Lozneanu L, Bagnoli M, Ramoni C, Canevari S, Mezzanzanica D, Iorio E, Canese R.

Oncotarget. 2017 Jul 5;8(33):55022-55038. doi: 10.18632/oncotarget.18992. eCollection 2017 Aug 15.

14.

Perfusion of isolated rat kidney with Mesenchymal Stromal Cells/Extracellular Vesicles prevents ischaemic injury.

Gregorini M, Corradetti V, Pattonieri EF, Rocca C, Milanesi S, Peloso A, Canevari S, De Cecco L, Dugo M, Avanzini MA, Mantelli M, Maestri M, Esposito P, Bruno S, Libetta C, Dal Canton A, Rampino T.

J Cell Mol Med. 2017 Dec;21(12):3381-3393. doi: 10.1111/jcmm.13249. Epub 2017 Jun 21.

15.

β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.

Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeglia M, Pricl S, Verderio P, Bottelli S, Fiore M, Stacchiotti S, Palassini E, Gronchi A, Pilotti S, Perrone F.

Mol Oncol. 2017 Nov;11(11):1495-1507. doi: 10.1002/1878-0261.12101. Epub 2017 Sep 29.

16.

Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?

Tonella L, Giannoccaro M, Alfieri S, Canevari S, De Cecco L.

Curr Treat Options Oncol. 2017 May;18(5):32. doi: 10.1007/s11864-017-0472-2. Review.

PMID:
28474265
17.

New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs).

Negri T, Brich S, Bozzi F, Volpi CV, Gualeni AV, Stacchiotti S, De Cecco L, Canevari S, Gloghini A, Pilotti S.

Oncotarget. 2017 May 16;8(20):32492-32504. doi: 10.18632/oncotarget.16477.

18.

Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer.

De Cecco L, Giannoccaro M, Marchesi E, Bossi P, Favales F, Locati LD, Licitra L, Pilotti S, Canevari S.

Genes (Basel). 2017 Jan 14;8(1). pii: E35. doi: 10.3390/genes8010035.

19.

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF, Karagiannis SN.

Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17.

20.

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, Valdagni R, Mezzanzanica D, Boerman O, Canevari S, Figini M.

Oncotarget. 2017 Feb 14;8(7):10919-10930. doi: 10.18632/oncotarget.14229.

21.

Axl in ovarian cancer: a step forward for clinical breakthrough?

Sensi M, Canevari S, Tomassetti A.

Oncotarget. 2016 Dec 6;7(49):80105-80106. doi: 10.18632/oncotarget.13457. No abstract available.

22.

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.

Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S.

Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.

23.

Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.

Lozneanu L, Pinciroli P, Ciobanu DA, Carcangiu ML, Canevari S, Tomassetti A, Căruntu ID.

Anticancer Res. 2016 Aug;36(8):4155-63.

PMID:
27466525
24.

In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.

Canese R, Mezzanzanica D, Bagnoli M, Indraccolo S, Canevari S, Podo F, Iorio E.

Front Oncol. 2016 Jun 28;6:164. doi: 10.3389/fonc.2016.00164. eCollection 2016. Review.

25.

Choline Metabolism Alteration: A Focus on Ovarian Cancer.

Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R, Podo F, Canevari S, Iorio E, Mezzanzanica D.

Front Oncol. 2016 Jun 22;6:153. doi: 10.3389/fonc.2016.00153. eCollection 2016. Review.

26.

Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues.

Veneroni S, Dugo M, Daidone MG, Iorio E, Valeri B, Pinciroli P, De Bortoli M, Marchesi E, Miodini P, Taverna E, Ricci A, Canevari S, Pelosi G, Bongarzone I.

Biopreserv Biobank. 2016 Dec;14(6):480-490. Epub 2016 Jul 12.

PMID:
27403896
27.

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group.

Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9.

28.

Whole exome sequencing and single nucleotide polymorphism array analyses to identify germline alterations in genes associated with testosterone metabolism in a patient with androgen insensitivity syndrome and early-onset colorectal cancer.

Disciglio V, Devecchi A, Palumbo O, Carella M, Penso D, Milione M, Valle G, Pierotti MA, Vitellaro M, Bertario L, Canevari S, Signoroni S, De Cecco L.

Chin J Cancer. 2016 Jun 7;35(1):51. doi: 10.1186/s40880-016-0115-1.

29.

Targeting folate receptor alpha for cancer treatment.

Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN.

Oncotarget. 2016 Aug 9;7(32):52553-52574. doi: 10.18632/oncotarget.9651. Review.

30.

Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.

Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L.

Clin Cancer Res. 2016 Aug 1;22(15):3961-70. doi: 10.1158/1078-0432.CCR-15-2547. Epub 2016 Feb 26.

31.

Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.

Frigerio B, Benigni F, Luison E, Seregni E, Pascali C, Fracasso G, Morlino S, Valdagni R, Mezzanzanica D, Canevari S, Figini M.

Immunol Lett. 2015 Nov;168(1):105-10. doi: 10.1016/j.imlet.2015.09.012. Epub 2015 Sep 25.

PMID:
26404855
32.

Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma.

Cecchetti S, Bortolomai I, Ferri R, Mercurio L, Canevari S, Podo F, Miotti S, Iorio E.

PLoS One. 2015 Sep 24;10(9):e0136120. doi: 10.1371/journal.pone.0136120. eCollection 2015.

33.

Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression.

Malaponte G, Hafsi S, Polesel J, Castellano G, Spessotto P, Guarneri C, Canevari S, Signorelli SS, McCubrey JA, Libra M.

Biochim Biophys Acta. 2016 Mar;1863(3):483-489. doi: 10.1016/j.bbamcr.2015.09.018. Epub 2015 Sep 14.

34.

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

Pinciroli P, Won H, Iyer G, Canevari S, Colecchia M, Giannatempo P, Raggi D, Pierotti MA, De Braud FG, Solit DB, Rosenberg JE, Berger MF, Necchi A.

Clin Genitourin Cancer. 2016 Feb;14(1):e81-90. doi: 10.1016/j.clgc.2015.07.017. Epub 2015 Aug 7. No abstract available.

35.

Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.

Rea K, Pinciroli P, Sensi M, Alciato F, Bisaro B, Lozneanu L, Raspagliesi F, Centritto F, Cabodi S, Defilippi P, Avanzi GC, Canevari S, Tomassetti A.

Oncotarget. 2015 Oct 13;6(31):30859-75. doi: 10.18632/oncotarget.5087.

36.

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.

Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E.

Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.

37.

Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells.

De Cecco L, Capaia M, Zupo S, Cutrona G, Matis S, Brizzolara A, Orengo AM, Croce M, Marchesi E, Ferrarini M, Canevari S, Ferrini S.

PLoS One. 2015 Aug 25;10(8):e0134706. doi: 10.1371/journal.pone.0134706. eCollection 2015.

38.

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.

Ledermann JA, Canevari S, Thigpen T.

Ann Oncol. 2015 Oct;26(10):2034-43. doi: 10.1093/annonc/mdv250. Epub 2015 Jun 10. Review.

PMID:
26063635
39.

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.

Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbareschi M, Raspagliesi F, Mezzanzanica D, Canevari S.

Oncotarget. 2015 Apr 30;6(12):9643. No abstract available.

40.

Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data.

De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, Locati L, Licitra L, Canevari S.

Oncotarget. 2015 Apr 20;6(11):9627-42.

41.

Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma.

Granata A, Nicoletti R, Perego P, Iorio E, Krishnamachary B, Benigni F, Ricci A, Podo F, Bhujwalla ZM, Canevari S, Bagnoli M, Mezzanzanica D.

Oncotarget. 2015 May 10;6(13):11216-30.

42.

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.

Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, De Braud F, Canevari S, Anichini A, Sensi M.

Oncotarget. 2015 Mar 10;6(7):5118-33.

43.

Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo.

Quarta A, Bernareggi D, Benigni F, Luison E, Nano G, Nitti S, Cesta MC, Di Ciccio L, Canevari S, Pellegrino T, Figini M.

Nanoscale. 2015 Feb 14;7(6):2336-51. doi: 10.1039/c4nr04426f.

PMID:
25504081
44.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD.

Clin Exp Metastasis. 2015 Jan;32(1):29-38. doi: 10.1007/s10585-014-9688-8. Epub 2014 Nov 15.

45.

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Cell Death Dis. 2014 Oct 2;5:e1434. doi: 10.1038/cddis.2014.410.

46.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S.

Oncotarget. 2014 Aug 15;5(15):5965-77.

47.

Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor.

De Cecco L, Bossi P, Locati L, Canevari S, Licitra L.

Ann Oncol. 2014 Aug;25(8):1628-35. doi: 10.1093/annonc/mdu173. Epub 2014 May 14.

PMID:
24827125
48.

Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.

Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogi F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M.

Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672.

49.

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.

Pisanu ME, Ricci A, Paris L, Surrentino E, Liliac L, Bagnoli M, Canevari S, Mezzanzanica D, Podo F, Iorio E, Canese R.

Br J Cancer. 2014 Feb 4;110(3):625-35. doi: 10.1038/bjc.2013.758. Epub 2013 Dec 12.

50.

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.

Granata A, Nicoletti R, Tinaglia V, De Cecco L, Pisanu ME, Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M, Mezzanzanica D.

Br J Cancer. 2014 Jan 21;110(2):330-40. doi: 10.1038/bjc.2013.729. Epub 2013 Nov 26.

Supplemental Content

Loading ...
Support Center